ATBF1 Inhibitors
ATBF1 inhibitors belong to a distinct chemical class characterized by their ability to selectively target and modulate the activity of ATBF1, an important transcription factor. The acronym ATBF1 stands for AT-binding transcription factor 1, which is a protein that plays a crucial role in the regulation of gene expression. This transcription factor is primarily recognized for its involvement in diverse cellular processes, including cell proliferation, differentiation, and apoptosis. The inhibitors designed to interact with ATBF1 typically exert their effects by binding to specific regions of the protein, thereby modulating its transcriptional activity. The chemical structures of ATBF1 inhibitors vary, reflecting the diverse strategies employed in their development, but they share a common objective of interfering with the normal functioning of ATBF1.
ATBF1 inhibitors involves disrupting the interaction between ATBF1 and its target DNA sequences, influencing downstream gene expression patterns. By selectively inhibiting ATBF1, these compounds have the potential to impact various cellular pathways, making them valuable tools for elucidating the biological functions associated with ATBF1. Additionally, the development of ATBF1 inhibitors represents a promising avenue for research in understanding the intricate regulatory networks that govern cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 inhibits BET bromodomain proteins, which can regulate transcription and potentially downregulate ATBF1 expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor, which can alter chromatin structure and potentially affect ATBF1-related gene expression. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine inhibits the Hedgehog signaling pathway, which might intersect with ATBF1-regulated processes in development. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is involved in cell growth and proliferation, potentially influencing ATBF1 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can modulate various signaling pathways, potentially altering ATBF1 functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can affect transcription factors and thereby might impact ATBF1 activity indirectly. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which could affect stress response pathways that intersect with ATBF1's role. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor that could modify cell signaling pathways relevant to ATBF1 function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor, which can affect protein degradation pathways, potentially influencing ATBF1 stability. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide affects the degradation of transcription factors, and it may indirectly affect ATBF1-related pathways. | ||||||